Federated Hermes Inc. Makes New Investment in Abivax SA Sponsored ADR $ABVX

Federated Hermes Inc. purchased a new stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 99,500 shares of the company’s stock, valued at approximately $8,448,000. Federated Hermes Inc. owned about 0.13% of Abivax as of its most recent filing with the SEC.

Other institutional investors have also recently modified their holdings of the company. First Horizon Corp acquired a new position in Abivax in the 3rd quarter worth approximately $36,000. Bank of America Corp DE boosted its holdings in shares of Abivax by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after acquiring an additional 1,990 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of Abivax by 34.3% in the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after acquiring an additional 2,595 shares during the period. Covestor Ltd purchased a new position in shares of Abivax during the third quarter worth $96,000. Finally, XTX Topco Ltd acquired a new position in Abivax during the second quarter valued at $139,000. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

Abivax Price Performance

Abivax stock opened at $111.15 on Monday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. The company’s fifty day moving average price is $123.33 and its 200 day moving average price is $97.30. The stock has a market capitalization of $8.72 billion, a P/E ratio of -26.59 and a beta of 0.81. Abivax SA Sponsored ADR has a 1 year low of $4.77 and a 1 year high of $148.83.

Abivax (NASDAQ:ABVX) last announced its earnings results on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The firm had revenue of ($4.92) million for the quarter. As a group, equities research analysts anticipate that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ABVX. Barclays initiated coverage on Abivax in a research note on Monday, October 13th. They set an “overweight” rating and a $142.00 price objective for the company. Morgan Stanley lifted their price target on Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a research report on Friday, January 9th. Citigroup reissued a “market outperform” rating on shares of Abivax in a report on Thursday, January 8th. Wall Street Zen cut shares of Abivax from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Finally, Guggenheim reaffirmed a “buy” rating and set a $175.00 target price on shares of Abivax in a report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $135.08.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.